Trial Profile
Clearance of the probiotic strain Escherichia coli Nissle 1917 in the gastrointestinal tract of healthy volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2017
Price :
$35
*
At a glance
- Drugs Non-pathogenic E coli (Primary)
- Indications Inborn urea cycle disorders; Inflammatory bowel diseases; Phenylketonuria
- Focus Therapeutic Use
- Sponsors Synlogic
- 10 May 2017 Status changed from recruiting to completed.
- 13 Sep 2016 New trial record